Golimumab
Simponi (SC) & Simponi Aria (IV)
Golimumab — Approved Indications
| Indication | Population | Formulation | Status |
|---|---|---|---|
| Rheumatoid arthritis — moderate to severe | Adults | Simponi (SC) with MTX; Simponi Aria (IV) with MTX | FDA Approved |
| Psoriatic arthritis | Adults (SC); ≥2 years (IV) | Simponi (SC); Simponi Aria (IV) | FDA Approved |
| Ankylosing spondylitis | Adults | Simponi (SC); Simponi Aria (IV) | FDA Approved |
| Ulcerative colitis — moderate to severe | Adults and children ≥2 years (≥15 kg) | Simponi (SC) only | FDA Approved (pediatric: Oct 2025) |
| Polyarticular JIA | ≥2 years | Simponi Aria (IV) only | FDA Approved |
Golimumab is the only TNF-α inhibitor available in both a monthly subcutaneous formulation (Simponi) and a weight-based intravenous formulation (Simponi Aria). As a fully human IgG1κ monoclonal antibody with a molecular weight of approximately 150–151 kDa, it binds both soluble and transmembrane TNF-α. Golimumab was first approved in the US in 2009 (Simponi SC); Simponi Aria (IV) was approved in 2013 for RA and subsequently expanded to PsA and AS. For RA, golimumab must be used in combination with methotrexate. For PsA and AS, it can be used with or without MTX.
Simponi (SC) and Simponi Aria (IV) are separate products with different dosing regimens, concentrations, and indications. The safety and efficacy of switching between IV and SC formulations have not been established. Simponi Aria is NOT approved for ulcerative colitis. Clinicians should not interchange these products.
Golimumab Dosing by Clinical Scenario
Simponi (Subcutaneous) — Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| RA — with MTX (required) | 50 mg SC | 50 mg SC Q4W (monthly) | 50 mg Q4W | No loading dose; MTX required per FDA label; corticosteroids, NSAIDs, other non-biologic DMARDs may continue |
| Psoriatic arthritis | 50 mg SC | 50 mg SC Q4W | 50 mg Q4W | With or without MTX or non-biologic DMARDs |
| Ankylosing spondylitis | 50 mg SC | 50 mg SC Q4W | 50 mg Q4W | With or without MTX |
| Ulcerative colitis — induction/maintenance | 200 mg SC at Wk 0, 100 mg at Wk 2 | 100 mg SC Q4W | 100 mg Q4W | Adult doses shown; paediatric (≥2 years, ≥15 kg) dosing is weight-based. Only Simponi (SC); Simponi Aria (IV) is not approved for UC UC requires higher loading and maintenance doses than RA/PsA/AS |
Simponi Aria (Intravenous) — Adult Dosing
| Clinical Scenario | Starting Dose | Maintenance Dose | Maximum Dose | Notes |
|---|---|---|---|---|
| RA — with MTX (required) | 2 mg/kg IV at Wk 0 & 4 | 2 mg/kg IV Q8W | 2 mg/kg Q8W | 30-minute infusion; given with MTX Shorter infusion time than infliximab (≥2 h) |
| PsA / AS | 2 mg/kg IV at Wk 0 & 4 | 2 mg/kg IV Q8W | 2 mg/kg Q8W | Same weight-based regimen across RA, PsA, and AS for the IV formulation |
Golimumab SC (Simponi) offers the simplest dosing among subcutaneous TNF inhibitors for RA, PsA, and AS: a fixed 50 mg once monthly with no loading dose. This contrasts with adalimumab (Q2W), certolizumab pegol (loading dose then Q2W or Q4W), and etanercept (weekly). For UC, however, golimumab requires a higher-dose induction (200 mg/100 mg) followed by 100 mg monthly maintenance. Concomitant MTX increases golimumab trough levels by approximately 52% in RA and reduces anti-drug antibody incidence from 7% to 2%.
Pharmacology
Mechanism of Action
Golimumab is a fully human IgG1κ monoclonal antibody with a molecular weight of approximately 150–151 kDa. It binds with high affinity to both soluble and transmembrane bioactive forms of human TNF-α, preventing binding to its receptors (TNFR1 and TNFR2) and thereby inhibiting TNF-α-mediated inflammatory signalling. Golimumab does not bind or neutralise lymphotoxin (TNF-β) or other TNF superfamily ligands. Unlike the chimeric antibody infliximab, golimumab’s fully human structure confers lower baseline immunogenicity. It does not lyse human monocytes expressing transmembrane TNF in the presence of complement or effector cells, though it does inhibit TNF-α-driven production of pro-inflammatory mediators including IL-6, ICAM-1, and MMP-3.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | SC bioavailability ~53%; Tmax 2–6 days; dose-proportional PK; IV: 100% bioavailability | Monthly SC dosing feasible despite moderate bioavailability due to long half-life |
| Distribution | Vd 58–126 mL/kg; primarily distributed in the circulatory system | Limited extravascular distribution typical of IgG monoclonal antibodies |
| Metabolism | Exact metabolic pathway unknown; presumed proteolytic catabolism; not CYP-mediated | No conventional CYP interactions; however, TNF normalisation may restore CYP450 activity |
| Elimination | Terminal t½ ~12–14 days; steady-state trough with MTX ~0.4–0.6 mcg/mL (RA); anti-drug antibodies decrease trough levels | MTX co-administration increases trough by ~52% (RA), 36% (PsA), 21% (AS) and reduces ADA from 7% to 2% |
Side Effects
Adverse reaction data below are from the pooled Phase 3 controlled trials in RA, PsA, and AS (Simponi SC, Table 1 of FDA PI; through Week 16), unless otherwise stated.
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Upper respiratory tract infections (nasopharyngitis, pharyngitis, laryngitis, rhinitis) | 16% vs 12% placebo | Most common adverse reaction; generally mild and self-limiting |
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Injection site reactions (erythema, urticaria, induration, pain, bruising, pruritus) | 6% | Majority mild to moderate; injection site erythema most frequent |
| Nasopharyngitis | 6% | Part of the broader URI pattern; overlaps with URTI reporting |
| ALT increased | 4% | Monitor liver function; more common with concurrent MTX |
| Hypertension | 3% | Monitor blood pressure periodically |
| AST increased | 3% | Usually asymptomatic; evaluate if persistent or rising |
| Bronchitis | 2% | Part of respiratory infection spectrum |
| Dizziness | 2% | Usually transient |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Serious infections (sepsis, pneumonia, cellulitis, abscess, TB) | 1.4% vs 1.3% placebo (Wk 16); 5.7/100 PY longer-term | Any time during treatment | Discontinue golimumab; initiate appropriate antimicrobials |
| Tuberculosis | 0.23/100 PY vs 0 placebo | Months; pulmonary and extrapulmonary | Screen before and during therapy; treat latent TB before starting; stop for active TB |
| Lymphoma | Higher than general population | Months to years | Evaluate unexplained lymphadenopathy; RA patients already at elevated baseline risk |
| Heart failure (new onset or worsening) | Rare (class effect) | Weeks to months | Use with caution in CHF; discontinue if worsening |
| Demyelinating disease | Rare | Weeks to months | Discontinue; refer to neurology; includes MS, GBS, optic neuritis |
| Hypersensitivity / anaphylaxis | Rare (post-marketing) | During or after injection/infusion | Discontinue permanently; no anaphylactic reactions in Phase 2/3 SC trials |
| Lupus-like syndrome | Rare | Months | Discontinue; symptoms typically resolve |
| HBV reactivation | Rare (carriers at risk) | During or after treatment | Screen all patients before initiation; monitor carriers; start antiviral if reactivation |
| Cytopenias (pancytopenia, leukopenia, neutropenia, aplastic anaemia) | Rare | Variable | Urgent CBC if persistent fever, bruising, or pallor; consider discontinuation |
Golimumab has a notably low treatment discontinuation rate (2% vs 3% placebo through Week 16 in RA/PsA/AS), which is lower than several other TNF inhibitors at equivalent time points. No anaphylactic reactions were observed in Phase 2 or 3 SC trials, though serious systemic hypersensitivity reactions have been reported post-marketing. Injection site reactions (6%) are generally mild and mostly manifest as erythema.
Drug Interactions
No formal drug interaction studies have been conducted with golimumab. Population PK analysis shows concomitant MTX, NSAIDs, oral corticosteroids, and sulfasalazine do not significantly influence golimumab clearance. However, TNF-α normalisation may restore CYP450 activity suppressed by chronic inflammation.
Monitoring
- TB ScreeningBefore initiation; periodically
RoutineTST or IGRA before starting. TB rate 0.23/100 PY in clinical trials. Treat latent TB before initiation. Repeat annually for patients with ongoing risk factors. - Hepatitis BBefore initiation; during and after in carriers
RoutineScreen all patients (HBsAg, anti-HBc, anti-HBs). Monitor HBV carriers for reactivation during and for several months after therapy. - Liver FunctionBaseline; periodically
RoutineALT elevations in 4%, AST in 3% of patients. More common with concurrent MTX. Monitor periodically. - CBCBaseline; periodically
RoutineReports of pancytopenia, leukopenia, neutropenia, aplastic anaemia, and thrombocytopenia. Urgently check if persistent fever, bruising, or pallor. - Signs of InfectionEvery visit
RoutineAssess for fever, cough, weight loss, night sweats, or focal symptoms at each encounter. - Skin ExaminationAnnually
RoutineMelanoma and Merkel cell carcinoma reported post-marketing with golimumab. - Heart FailureIf pre-existing
Trigger-BasedNot formally studied in CHF patients. Monitor for worsening dyspnoea, oedema; discontinue if worsening. - Neurological SymptomsIf new symptoms
Trigger-BasedEvaluate for demyelinating disease (MS, GBS, optic neuritis). Discontinue and refer.
Contraindications & Cautions
Absolute Contraindications
- None listed in the US FDA label — the Simponi PI does not contain a formal Contraindications section listing specific contraindications (unlike infliximab). However, serious hypersensitivity reactions have occurred post-marketing and should preclude re-administration.
Relative Contraindications (Specialist Input Recommended)
- Active serious infection — do not initiate until fully controlled.
- Active or untreated latent TB.
- Pre-existing demyelinating disease (MS, optic neuritis, GBS).
- History of serious hypersensitivity to golimumab (angioedema, anaphylaxis).
- History of malignancy — risk-benefit assessment required.
Use with Caution
- Heart failure — not studied in CHF; worsening and new-onset CHF reported with TNF blockers as a class.
- Elderly (≥65 years) — higher infection risk in the general geriatric population.
- HBV carriers — monitor for reactivation.
- Pregnancy — golimumab crosses the placenta during the third trimester. Avoid live vaccines in exposed infants for 6 months after the mother’s last dose.
Serious Infections: Patients treated with golimumab are at increased risk for developing serious infections leading to hospitalisation or death, including TB, invasive fungal infections, and bacterial, viral, and other opportunistic infections. Discontinue golimumab if a serious infection or sepsis develops.
Malignancy: Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers. Post-marketing cases of HSTCL have occurred, particularly in young males with IBD on concurrent azathioprine or 6-mercaptopurine.
Patient Counselling
Purpose of Therapy
Golimumab works by blocking a protein called TNF-alpha that drives inflammation in conditions like rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. By reducing this inflammation, it helps relieve joint pain, stiffness, and swelling, and can slow joint damage. It is available as a monthly injection under the skin (Simponi) or as an intravenous infusion given every 8 weeks (Simponi Aria).
How to Take
For the subcutaneous formulation (Simponi), patients can self-inject after proper training using a prefilled autoinjector or syringe. For RA, PsA, and AS, the dose is one 50 mg injection per month. For ulcerative colitis, higher doses are used for the first two injections. Injections should be given in the thigh or abdomen, rotating sites each time. Store in the refrigerator; do not freeze.
Sources
- Janssen Biotech, Inc. SIMPONI (golimumab) injection, for subcutaneous use. Full Prescribing Information. Revised 2025. FDA LabelPrimary source for SC dosing, indications, adverse reactions, and PK data across RA, PsA, AS, and UC.
- Janssen Biotech, Inc. SIMPONI ARIA (golimumab) injection, for intravenous use. Full Prescribing Information. Revised 2021. FDA LabelIV formulation label for RA, PsA, AS, and pJIA; includes weight-based dosing and 30-minute infusion guidance.
- Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis. 2009;68(6):789-796. doi:10.1136/ard.2008.099010Pivotal phase III trial (RA Trial RA-2) demonstrating golimumab 50 mg + MTX superiority over MTX alone in RA.
- Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study). Lancet. 2009;374(9685):210-221. doi:10.1016/S0140-6736(09)60506-7RA Trial RA-1 in patients previously treated with TNF inhibitors; established golimumab efficacy in TNF-experienced patients.
- Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis (GO-REVEAL). Arthritis Rheum. 2009;60(4):976-986. doi:10.1002/art.24403Pivotal PsA trial demonstrating ACR20/50/70 responses and inhibition of structural damage with golimumab 50 mg/100 mg.
- Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial (GO-RAISE). Arthritis Rheum. 2008;58(11):3402-3412. doi:10.1002/art.23969Pivotal AS trial demonstrating ASAS20/40 responses with golimumab 50 mg and 100 mg monthly.
- Sandborn WJ, Feagan BG, Marano C, et al. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis (PURSUIT-Maintenance). Gastroenterology. 2014;146(1):96-109.e1. doi:10.1053/j.gastro.2013.06.010Maintenance phase of PURSUIT demonstrating sustained clinical response, remission, and mucosal healing with golimumab 100 mg Q4W in UC.
- Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Care Res. 2021;73(7):924-939. doi:10.1002/acr.24596Current ACR guideline positioning TNF inhibitors including golimumab as preferred biologics after csDMARD failure.
- Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis: 2022 update. Ann Rheum Dis. 2023;82(1):3-18. doi:10.1136/ard-2022-223356EULAR consensus on biologic DMARD sequencing in RA management.
- Golimumab. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. NCBI BookshelfPeer-reviewed pharmacology overview covering mechanism, PK parameters, dosing, and adverse effects.
- Zhuang Y, Xu Z, de Vries DE, et al. Pharmacokinetics of golimumab in patients with active rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. J Clin Pharmacol. 2012;52(11):1656-1668. doi:10.1177/0091270011421911Pop PK analysis characterising golimumab disposition and the influence of MTX, body weight, and ADA on clearance.